Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Effectiveness and Safety of Ibrutinib in Patients with Mantle Cell Lymphoma (MCL) in Belgian Routine Clinical Practice: 3-Year Follow-up

Vibeke Vergote, Sylvia Snauwaert, Kirsten Saevels, Birgit De Beleyr, Marjolein Lahaye, Ariane Maes, Hilde Demuynck, Sarah Debussche, Marc Andre

Blood (2022) 140 (Supplement 1): 3661–3662.

https://doi.org/10.1182/blood-2022-158504

Published: 2022

Journal Articles

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

Blood (2014) 124 (21): 3458.

https://doi.org/10.1182/blood.V124.21.3458.3458

Published: 2014

Journal Articles

The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Mary Frances McMullin, MD, Claire N Harrison, DM FRCP FRCPath, Dietger Niederwieser, Hilde Demuynck, Nadja Jakel, Andres Sirulnik, MD, PhD, Mari McQuity, RN, MPH, Viktoriya Stalbovskaya, PhD, Christian Recher, MD, Koen Theunissen, MD, Heinz Gisslinger, MD, Jean-Jacques Kiladjian, MD, PhD, Haifa-Kathrin Al- Ali

Blood (2012) 120 (21): 2838.

https://doi.org/10.1182/blood.V120.21.2838.2838

Published: 2012

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

Anemia and the Use of Erythropoietic-Stimulating Agents with Ruxolitinib in the COMFORT-II Study

Mary Frances McMullin, MD, Claire N. Harrison, DM, FRCP, FRCPath, Dietger Niederwieser, MD, Hilde Demuynck, MD, PhD, Nadja Jäckel, Andres Sirulnik, MD, PhD, Alison Wearver, PhD, Viktoriya Stalbovskaya, MD, PhD, Jean-Jacques Kiladjian, MD, PhD, Haifa Kathrin Al-Ali, MD

Blood (2011) 118 (21): 5147.

https://doi.org/10.1182/blood.V118.21.5147.5147

Published: 2011

Journal Articles

International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.

Michel Delforge, MD, PhD, Hadewijch De Samblanx, Hilde Demuynck, Greet Bries, Philippe Mineur, Nathalie Meuleman, Fritz Offner, Chantal Doyen, Walter Feremans, Ann Van de Velde, Christophe Ravoet, Isabelle Vande Broek, Jan Van Droogenbroeck, Gabry Kuijten-Celzo, Joris Diels, Rita Ganguly, Ravinder Dhawan

Blood (2009) 114 (22): 4523.

https://doi.org/10.1182/blood.V114.22.4523.4523

Published: 2009

Journal Articles

Treatment of Older Patients, 40 to 70 Years of Age, with Acute Lymphoblastic Leukemia According to a Chemotherapy Regimen That Includes a Novel Pre-Phase for Rapid Tumor Load Reduction. Results of the Dutch-Belgian HOVON-71 Study.

Simon M. G. J. Daenen, Bronno van der Holt, Adriaan W. Dekker, Roelof Willemze, Anita Rijneveld, Bart J. Biemond, Petra Muus, Arjan A van de Loosdrecht, Harry Schouten, M. van Marwijk Kooy, Dimitri Breems, Johan Maertens, Hilde Demuynck, Pierre W Wijermans, Shulamiet Wittebol, Ellen W. de Klerk, Jan J. Cornelissen

Blood (2009) 114 (22): 2028.

https://doi.org/10.1182/blood.V114.22.2028.2028

Published: 2009

Journal Articles

BMI1 , the Polycomb-Group Gene, Is Recurrently Targeted by Genomic Rearrangements in Progressive B-Cell Leukemia/Lymphoma.

Leila Rouhi, MD, Natalie Put, MD, Thomas Tousseyn, MD, PhD, Julio Finalet Ferreiro, Wim De Kelver, Hilde Demuynck, MD, Johan Verschuere, MD, Ivan Théate, MD, Carmen Vicente, Lucienne Michaux, MD, PhD, Chris De Wolf-Peeters, MD, PhD, Peter Vandenberghe, MD, PhD, Jan Cools, PhD, Iwona Wlodarska, PhD

Blood (2009) 114 (22): 1099.

https://doi.org/10.1182/blood.V114.22.1099.1099

Published: 2009

Journal Articles

The T(14;20)(q32;q12) : A Rare Cytogenetic Change in Multiple Myeloma Associated with Poor Outcome

Marie-Christiane Vekemans, Heidi Lemmens, Chantal Doyen, Greet Bries, HIlde Demuynck, Pascal Pierre, Jan Lemmens, Peter Meeus, Michel Delforge, Deborah Bauwens, Iwona Wlodarska, Peter Vandenberghe, Lucienne Michaux

Blood (2008) 112 (11): 2718.

https://doi.org/10.1182/blood.V112.11.2718.2718

Published: 2008

Journal Articles

Gain-of-Function WASP Mutations in Pediatric and Adult Patients with Myelodysplasia or AML.

Karolien Beel, MD, Els Schollen, PhD, An Uyttebroeck, MD, Gregor Verhoef, MD PhD, Hilde Demuynck, MD PhD, Koen Devriendt, MD PhD, Peter Vandenberghe, MD PhD

Blood (2006) 108 (11): 4516.

https://doi.org/10.1182/blood.V108.11.4516.4516

Published: 2006

Journal Articles

Fludarabine Phosphate-Based Nonmyeloablative Stem Cell Transplantation in the Elderly Patients: A BHS Study.

Dominique Bron, MD, PhD, Pierre Zachée, MD, Johan Maertens, MD, Koen Theunissen, MD, Augustin Ferrant, MD, PhD, Philippe Martiat, MD, PhD, Chantal Doyen, MD, Luc Noens, MD, Wilfried Schroyens, MD, Dominique Sellesslag, MD, Hilde Demuynck, MD, Rick Schots, MD, PhD, Anne De Meuter, Marc Boogaerts, MD, PhD

Blood (2004) 104 (11): 5046.

https://doi.org/10.1182/blood.V104.11.5046.5046

Published: 2004

Journal Articles

Incidence and Outcome of Hepatic Veno-Occlusive Disease After Blood or Marrow Transplantation: A Prospective Cohort Study of the European Group for Blood and Marrow Transplantation

Blood (1998) 92 (10): 3599–3604.

https://doi.org/10.1182/blood.V92.10.3599

Published: 1998

NARROW

Effectiveness and Safety of Ibrutinib in Patients with Mantle Cell Lymphoma (MCL) in Belgian Routine Clinical Practice: 3-Year Follow-up

Impact of Response Quality on Survival Outcomes in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Results from the First Trial

The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Anemia and the Use of Erythropoietic-Stimulating Agents with Ruxolitinib in the COMFORT-II Study

International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.

Treatment of Older Patients, 40 to 70 Years of Age, with Acute Lymphoblastic Leukemia According to a Chemotherapy Regimen That Includes a Novel Pre-Phase for Rapid Tumor Load Reduction. Results of the Dutch-Belgian HOVON-71 Study.

BMI1 , the Polycomb-Group Gene, Is Recurrently Targeted by Genomic Rearrangements in Progressive B-Cell Leukemia/Lymphoma.

The T(14;20)(q32;q12) : A Rare Cytogenetic Change in Multiple Myeloma Associated with Poor Outcome

Gain-of-Function WASP Mutations in Pediatric and Adult Patients with Myelodysplasia or AML.

Fludarabine Phosphate-Based Nonmyeloablative Stem Cell Transplantation in the Elderly Patients: A BHS Study.

Incidence and Outcome of Hepatic Veno-Occlusive Disease After Blood or Marrow Transplantation: A Prospective Cohort Study of the European Group for Blood and Marrow Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only